SCHEMBL15919616

SCHEMBL15919616

CCS(=O)(=O)NCCCOc1ccc(-c2ccc(-c3cc(C(=O)NN)c4cnccc4n3)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.47
PLA2G2A P14555 3/20 0.47
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
HTT P42858 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
GAA P10253 1/20 0.47
RAB9A P51151 3/20 0.45
KMT2A Q03164 2/20 0.45
MAPT P10636 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
NPC1 O15118 1/20 0.45
HSP90AA1 P07900 1/20 0.45
ALOX12 P18054 1/20 0.45
POLB P06746 6/20 0.45
PDE10A Q9Y233 1/20 0.45
TP53 P04637 2/20 0.44
MEN1 O00255 1/20 0.44
DHODH Q02127 1/20 0.43
PRNP P04156 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17313846 0.97 LMNA (0.48) LMNAPLA2G2AKDM4EALDH1A1HTT
SCHEMBL15905355 0.93 KDM4E (0.45) LMNAPLA2G2AKDM4EALDH1A1HTT
SCHEMBL15905541 0.91 PLA2G2A (0.45) LMNAPLA2G2AKDM4EALDH1A1HTT
SCHEMBL15904883 0.90 ROCK2 (0.48) LMNAPLA2G2AKDM4EALDH1A1HTT
SCHEMBL15919497 0.90 ALDH1A1 (0.42) LMNAPLA2G2AKDM4EALDH1A1HTT
SCHEMBL15904789 0.89 TP53 (0.49) LMNAPLA2G2AKDM4EALDH1A1HTT
SCHEMBL15905409 0.88 KDM4E (0.48) LMNAPLA2G2AKDM4EALDH1A1HTT
SCHEMBL15904779 0.88 ALDH1A1 (0.44) LMNAPLA2G2AKDM4EALDH1A1HTT
SCHEMBL15905067 0.87 TP53 (0.50) LMNAPLA2G2AKDM4EALDH1A1HTT
SCHEMBL15905520 0.87 ALDH1A1 (0.42) LMNAPLA2G2AKDM4EALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US claimed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US claimed
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
WO-2014117090-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO LMNA 4266/4885PLA2G2A 1990/4885KDM4E 3322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.